TNFRSF17 and plasma cell myeloma: In hematologic malignancies such as multiple myeloma, where BITEs such as teclistamab (CD3 x BCMA), elranatamab (CD3 x BCMA) and talquetamab (CD3 x GPRC5D) are approved, potential mechanisms of resistance have been identified.